Inhibitors of synthetic lethal genes contributed to over 70% of the synergies observed (Fig. 1a, right), indicating that synthetic lethal genes play an indispensable role in the growth of KRAS-mutant cancers and represent applicable targets for treatment. The gene discussed is KRAS; the disease is cancer.